URGN Latest Press Releases

-- February 4, 2026 --

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit Globe Newswire 8:00 AM

-- January 5, 2026 --

Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy Globe Newswire 8:00 AM

-- December 5, 2025 --

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- November 25, 2025 --

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference Globe Newswire 8:00 AM

-- November 6, 2025 --

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial Globe Newswire 7:58 AM

-- November 4, 2025 --

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference Globe Newswire 8:00 AM

-- October 30, 2025 --

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 Globe Newswire 8:00 AM

-- October 27, 2025 --

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 Globe Newswire 8:00 AM

-- October 2, 2025 --

ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software